About Us

Cloudbreak Pharma is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.


Cloudbreak Pharma operates a capital efficient business model mostly based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and carry out Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

In addition to repurposing approved oral drugs for ocular use, we also have several early stage innovative programs, ranging from low risk formulation improvement of known ocular drugs, to higher risk development of new chemical entity (NCE) and biologics drugs for ocular indications with unmet needs.

The Cloudbreak Pharma management team has extensive experience with ocular drug discovery and development. In addition, Cloudbreak Pharma is supported by seasoned advisers and consultants.


Jinsong Ni, PhD Cloudbreak Therapeutics Founder and CEO

Jinsong Ni, Ph.D

Founder, Chief Executive Officer

Rebecca Chan, CPA, MBA, LLB

Director, Chief Financial Officer

Abu Abraham

Abu Abraham, MD

Chief Medical Officer

Van Dinh MBA Cloudbreak Therapeutics Co-Founder and COO

Van Dinh, MBA

Chief Operating Officer

我的專案 (1)

Rong Yang, Ph.D

Chief Scientific Officer


Greg Brooks, B.Sc

Chief Commercial Officer

WenKui Fang

W. Ken Fang, Ph.D

Chief Innovation Officer

Elizabeth Capan

Elizabeth Capan, J.D.

Chief Patent Officer

Scientific Advisory Board